NeurologyOnline.net

Neurology Xagena

Search results for "Carbidopa"

IPX066 ( Rytary ) is an oral, extended-release, capsule formulation of Carbidopa and Levodopa. A phase 3, randomised, double-blind, double-dummy study at 68 academic and clinical centres in North Amer ...


Levodopa / Carbidopa intestinal infusion represents one of the therapeutic options for advanced Parkinson’s disease patients with motor fluctuations and diskynesias unresponsive to other treatments. I ...


Several cases of syndrome of inappropriate antidiuresis induced by anti-Parkinson agents have been reported. A previous study has demonstrated that Pergolide ( Nopar ) and Pramipexole ( Mirapex, Mirap ...


Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that ...


The Food and Drug Administration ( FDA ) has approved Duopa ( Carbidopa and Levodopa ) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. Duopa is ...


A 7-year experience assessing safety and outcomes of Levodopa / Carbidopa intestinal gel infusion ( LCIG ) in 59 advanced Parkinson disease ( PD ) patients presenting motor fluctuations and severe dys ...


Levodopa-Carbidopa intestinal gel ( LCIG ) was evaluated for the treatment of dyskinesia in a subgroup of advanced Parkinson’s disease ( PD ) patients with relevant dyskinesia. Oral Levodopa therap ...


A study has compared baseline characteristics between patients with advanced Parkinson's disease who continued with Levodopa-Carbidopa intestinal gel [ LCIG; Duodopa; Duopa ] ( contLCIG ) and patients ...


A study has compared the effectiveness ( percentage of change in daily ON, OFF and dyskinesia times ) and tolerability of Levodopa-Carbidopa intestinal gel ( LCIG; Duodopa; Duopa ) in patients with Pa ...


Researchers have analyzed the evolution of non-motor symptoms and patients’ and neurologists’ clinical global impression ( CGI ) in advanced Parkinson's disease patients treated with Levodopa–Carbidop ...


Levodopa is the mainstay of Parkinson's disease ( PD ) treatment, but is often eventually associated with disabling motor complications in patients with advanced disease. The inability of perorally ...


In advanced Parkinson's disease ( PD ) patients, continuous intra-duodenal infusion of Levodopa/Carbidopa intestinal gel ( LCIG; Duodopa ) is an established approach in the management of motor complic ...


Severe polyneuropathy has been observed in a number of patients treated for Parkinson's disease with Levodopa/Carbidopa intestinal gel infusion ( Duodopa ). This may reflect a rare individual complica ...